---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-049658"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:31:39.283107+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma submits pre-IND to FDA for SPC-15 intranasal PTSD treatment

## Summary
- SPC-15 is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder.
- Pre-clinical data showed effective, consistent exposure in a non-GLP small animal study completed Feb 2024.
- Silo expects to finalize an exclusive worldwide license with Columbia University in H1 2024.
- Next steps: PIND and GLP studies both slated to commence in H2 2024 before IND submission.
- Only two FDA-approved PTSD drugs exist; SPC-15 aims to increase stress resilience in high-risk populations.

## SEC filing metadata
- accession: 0001213900-24-049658
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390024049658/0001213900-24-049658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390024049658/ea0207247-8k_silo.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-049658
- JSON: https://secwatch.observer/filing/0001213900-24-049658.json
- Plain text: https://secwatch.observer/filing/0001213900-24-049658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.